EGMN -- A Food and Drug Administration advisory on Sept. 16 panel voted 9-5 that the potential risks of the serotoninergic drug lorcaserin outweighed its potential benefits as a long-term treatment for weight loss in overweight and obese people and, therefore, did not support approval.
